Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Deloitte
US Army
Cerilliant
Cantor Fitzgerald
Express Scripts
Argus Health
Boehringer Ingelheim
Teva

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,180,194

« Back to Dashboard

Which drugs does patent 9,180,194 protect, and when does it expire?

Patent 9,180,194 protects AXIRON and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 9,180,194
Title:Method and composition for transdermal drug delivery
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
Inventor(s): Dipietro; Tony (Templestowe Lower, AU), Humberstone; Andrew (Vaud, CH), Gonda; Igor (South Yarra, AU), Watkinson; Adam (Lympne, GB), Setiawan; Kerrie (South Yarra, AU), Wilkins; Nina (Kensington, AU)
Assignee: ACRUX DDS PTY LTD (West Melbourne, Victoria, AU)
Application Number:14/509,404
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,180,194

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,180,194

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2005902902Jun 3, 2005

Non-Orange Book US Patents Family Members for Patent 9,180,194

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,435,944 Method and composition for transdermal drug delivery ➤ Try a Free Trial
8,993,520 Method and composition for transdermal drug delivery ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,180,194

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006254742 ➤ Try a Free Trial
Australia 2011202787 ➤ Try a Free Trial
Brazil PI0611134 ➤ Try a Free Trial
Canada 2610708 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Cerilliant
QuintilesIMS
Johnson and Johnson
Harvard Business School
Colorcon
Teva
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.